Press

Optimind Acquires MindSetting Institute to Integrate Three-Pronged Approach to its Business and Become Industry Leader in Psychedelic Enhanced Psychotherapy

Sep 20 • 4 min read

Optimind Pharma Corp. (CSE: OMND) an emerging provider of psychedelic therapies focused on improving the everyday quality of life for individuals who suffer from PTSD, anxiety, depression, and other mental illnesses or disabilities announces today its acquisition of MindSetting Institute, a leader in psychedelic enhanced therapy training and educational programming. The completion of this acquisition…

PSYC Completes Acquisition of Media Assets from Technical420, LLC

Sep 20 • 6 min read

PSYC Corporation (OTCPink: PSYC), a media leader focused on the emerging psychedelic and cannabis sectors, announced the signing and closing of an amended definitive agreement for its wholly owned subsidiary Spotlight Media Corp. (“SMC”) to acquire media-related assets from Technical420, LLC (“T420”) as well as certain assets of SB Partners, LLC, that include, but are not limited to, MushroomStocks.com and OnTheBids.com, as…

XPhyto Files Patent Application for Library of Novel Psychedelic Compounds

Sep 20 • 2 min read

XPhyto Therapeutics Corp. (CSE:XPHY | OTCQB:XPHYF | FSE:4XT) is pleased to report that it has filed a patent application for a significant library of novel psychedelic compounds. Each compound was designed to provide specific alterations in their respective biopharmaceutical properties. The library of compounds can be selected to target (personalize) the treatment of neuropsychiatric, and neurodegenerative,…

Psyence Group Receives Phase IIa Clinical Trial Approval from the UK Medicines and Healthcare Products Regulatory Agency

Sep 19 • 3 min read

Psyence Group Inc. (CSE: PSYG | OTCQB: PSYGF), a life science biotechnology company pioneering the use of natural psychedelics in mental health and well-being, is delighted to announce that it has received approval for its Phase IIa clinical trial from the Medicines and Healthcare products Regulatory Agency (MHRA), the UK equivalent regulatory body to Canada’s Health Canada…

Tryp Therapeutics Appoints Jim O’Neill as Chief Financial Officer

Sep 19 • 3 min read

Tryp Therapeutics Inc. (CSE: TRYP), a clinical-stage biotechnology company focused on developing psilocybin-based compounds for diseases with unmet medical needs, today announced that it has expanded its leadership team with the appointment of Jim O’Neill as its Chief Financial Officer. In his new role, Mr. O’Neill will oversee all aspects of Tryp’s finance and accounting organization….

Pages: 123456789101112131415161718192021222324252627282930313233343536373839404142434445464748495051525354555657585960616263646566676869707172737475767778798081828384858687888990919293949596979899100101102103104105106107108109110111112113114115116117118119120121122123124125126127128129130131132133134135136137138139140141142143144145146147148149150151152153154155156157158159160161162163164165166167168169170171172173174175176177178179180181182183184185186187188189190191192193194195196197198199200201202203204205206207208209210211212213214215216217218219220221222223224225226227228229230231232233234235236237238239240241242243244245246247248249250251252253254255256257258259260261262263264265266267268269270271272273274275276277278279280281282283284285286287288289290291292293294295296297298299300301302303304305306307308309310311312313314315316317318319320321322323324325326327328329330331332333334335336337338339340341342343344345346347348349350351352353354355356357358359360361362363364365366367368369370371372373374375376377378379380381382383384385386387388389390391392393394395396397398399400401402403404405406407408409410411412413414415416417418419420421422423424425426427428429430431432433434435436437438439440441